Discovery Labs Up 33% After Surfaxin Approved by the FDA
Shares of Discovery Labs (NASDAQ: DSCO) are up 33% after the company had its drug Surfaxin approved by the FDA.
The company announced that the United States Food and Drug Administration has approved SURFAXIN for the prevention of Respiratory Distress Syndrome in premature infants at high risk for RDS. SURFAXIN is the first synthetic, peptide-containing surfactant approved for use in neonatal medicine. Discovery Labs anticipates that SURFAXIN will be commercially available in the United States in late 2012.
"The approval of SURFAXIN is an important medical advancement for the neonatology community and parents of preterm infants who will soon have an effective alternative to animal-derived surfactants to prevent the development of RDS," said W. Thomas Amick, Chairman of the Board and Chief Executive Officer of Discovery Labs. "This is a significant milestone in our continuing efforts to develop a pipeline of products to further advance the standard of respiratory critical care."
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.